Drug-Induced Bullous Eruption – Decision Support Tool

Drug-Induced Bullous Eruption – Decision Support (HCP)

Drug-Induced Bullous Eruption – Decision Support (HCP)

Triage • Severity • Timing • Causality • Differential • Management • PV/Reg • Print Summary

1) Patient, Exposure & Timing

2) Presentation

Phenotype (suggested)

–

Severity tier

–

Risk window fit

–
Immediate safety: If SJS/TEN suspected → stop suspected drug now; urgent hospital evaluation. Protect skin/mucosa; fluids; pain control; ophthalmology if ocular symptoms.

3) Timing – TTO & Exposure at Onset

Tip: Set Start, Stop (last dose), and Onset dates above to auto-calculate.
Interpretation — second box: + = last dose before onset (stopped X days prior) • 0 = dose on day of onset • − = continued after onset.

Time-to-Onset class

–
Based on drug class & days

Exposure at onset

–
Derived from “last dose → onset”

Urgency hint

–
Admission more likely if severe and on-drug at onset
What counts as a “typical” window?
Many SJS/TEN reactions begin 7–21 days after first exposure (anticonvulsants, sulfonamides, nevirapine, some penicillins/cephalosporins). Allopurinol: 7–30 days (longer with renal impairment). Oxicam-type NSAIDs: 5–15 days. Re-exposure/FDE can be much faster (hours).

4) Causality – Quick Score (Naranjo-inspired)

Causality: –

5) Alternatives (look-alikes)

Checklist – exclude competing diagnoses

6) Management (auto-suggest)

    7) PV / Regulatory

    If serious + unexpected, expedited reporting may apply (often ≤15 calendar days). Include complete timeline, photos, biopsy/DIF, %BSA, mucosal sites, labs, and product details.

    8) Case Summary (auto-generated)

    Disclaimer: Decision support only; does not replace clinical judgment, dermatology consults, or local protocols.